Investigating MET Exon 14 Mutations in Patients With NSCLC
Mark M. Awad, MD, PhD, discusses the characterization of patients with non–small cell lung cancer who have MET exon 14 skipping alterations and potential acquired resistance mechanisms.
Impact of MET Inhibitors in MET Exon 14-Mutant NSCLC
Mark Awad, MD, PhD, medical oncologist, Dana-Farber Cancer Institute, discusses the impact of MET inhibitors on survival among patients with <em>MET</em> exon 14-mutant non–small cell lung cancer.